While the most important decisions made by the FDA in December were undoubtedly the Emergency Use Authorizations for two COVID-19 vaccines, the month also saw a number of firsts on the regulatory front, including the authorization of the first test allowing for at-home collection of patient samples to detect both COVID-19 and influenza A and B. Now, today’s article takes…
Both of the stocks highlighted in today’s article are clinical-stage biotechs, both are developing products to address the coronavirus pandemic (a vaccine in one case and a therapeutic in the other) – and both are “ultra-risky”. So what are the chances that either – or both – of these two ultra-risky stocks could make investors ultra wealthy? For more on…
Of all the companies working on the development of potential COVID-19 vaccines and therapeutics, the one highlighted in today’s article – a small Israel-based biotech that specializes in blood plasma-based treatments – is one of the least well-known. However, given that plasma-based therapies have already been shown to be effective in treating severe cases of COVID-19, this company could start…
It’s the most popular investing theme this year: COVID-19 vaccine producers. However, the recent reversal of fortunes for the stock of one biotech firm – whose stock had nearly tripled since the beginning of March when the firm announced it was working on a vaccine for the novel coronavirus – illustrates the risk involved with “chasing vaccine hype”. For more,…
“This is very disconcerting and very bad timing,” says Tracy Donaldson, a newly retired Floridian who had the extremely bad luck of retiring the same week the Dow dropped significantly on coronavirus fears. But while Donaldson’s guaranteed pension and Social Security mean he’ll be fine even in the event of a lengthy downturn, many retirees may find themselves in a…